专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

KR101822932B1 ＧＰＲ43의 활성평가법 有权
公开(公告)号：KR101822932B1
公开(公告)日：2018-01-30
申请号：KR1020170055610
申请日：2017-04-28
申请人： 한국생명공학연구원
发明人： 김선홍 , 이수의 , 곽영신 , 강종순 , 김문옥 , 오수진 , 이상구 , 이현준 , 조성찬
IPC分类号： C12Q1/02 , G01N33/52 , G01N33/68 , C12N15/85 , C12Q1/68
摘要： 본발명은 GPR43(G protein receptor 43) 활성조절물질의활성평가방법에관한것이다. 구체적으로, GPR43의활성에따라농도가변하는 cAMP를측정할수있는세포주를개발하였고, GPR43가활성화되면세포내로이동하는성질을이용하여 GPR43 및 GFP가융합되어발현되는세포주를개발하였으며, GPR43가활성화되면베타-어레스틴2와결합하는성질을이용하여 GPR43 및베타-어레스틴2에각각루시퍼라아제의단편을융합하여발현하는세포주를개발하여 GPR43 활성조절물질의활성평가로유용하게이용될수 있다.

2. 发明授权

KR101601828B1 크라이토싸이빈 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 당뇨, 인슐린 저항성 증후군 또는 이들의 합병증의 예방 또는 치료용 약학적 조성물 有权
标题翻译：用于预防或治疗糖尿病胰岛素抵抗综合征的组合物或其含有胞质蛋白衍生物或其药学上可接受的盐作为活性成分的并发症
公开(公告)号：KR101601828B1
公开(公告)日：2016-03-09
申请号：KR1020130082190
申请日：2013-07-12
申请人： 한국생명공학연구원
发明人： 정태숙 , 유익동 , 이상구 , 김언희 , 류인자 , 윤정현
IPC分类号： A61K31/4035 , C07D209/46 , A61P3/10 , A61P3/00
摘要： 본발명은크라이토싸이빈(clitocybin) 유도체또는이의약학적으로허용가능한염을유효성분으로함유하는당뇨또는이의합병증, 또는인슐린저항성증후군의예방또는치료용약학적조성물에관한것으로, 구체적으로크라이토싸이빈유도체는디펩티딜펩티데이즈-IV(Dipeptidyl peptidase; DPP-IV) 및알파-글루코시데이즈(α-glucosidase)의활성을유의적으로억제하므로, 당뇨또는이의합병증, 또는인슐린저항성증후군의예방또는치료용약학적조성물로유용하게사용될수 있다.

3. 发明授权

KR101524653B1 ＧＰＲ43의 활성평가법 有权
标题翻译：一种鉴定GPR43调节剂的方法
公开(公告)号：KR101524653B1
公开(公告)日：2015-06-03
申请号：KR1020120119623
申请日：2012-10-26
申请人： 한국생명공학연구원
发明人： 김선홍 , 이수의 , 곽영신 , 강종순 , 김문옥 , 오수진 , 이상구 , 이현준 , 조성찬
IPC分类号： C12Q1/02 , G01N33/52 , C12N15/85 , G01N33/68
摘要： 본발명은 GPR43(G protein receptor 43) 활성조절물질의활성평가방법에관한것이다. 구체적으로, GPR43의활성에따라농도가변하는 cAMP를측정할수있는세포주를개발하였고, GPR43가활성화되면세포내로이동하는성질을이용하여 GPR43 및 GFP가융합되어발현되는세포주를개발하였으며, GPR43가활성화되면베타-어레스틴2와결합하는성질을이용하여 GPR43 및베타-어레스틴2에각각루시퍼라아제의단편을융합하여발현하는세포주를개발하여 GPR43 활성조절물질의활성평가로유용하게이용될수 있다.

4. 发明公开

KR1020150020640A ＧＰＲ43의 활성평가법 有权
标题翻译：一种鉴定GPR43调节剂的方法
公开(公告)号：KR1020150020640A
公开(公告)日：2015-02-26
申请号：KR1020150003239
申请日：2015-01-09
申请人： 한국생명공학연구원
发明人： 김선홍 , 이수의 , 곽영신 , 강종순 , 김문옥 , 오수진 , 이상구 , 이현준 , 조성찬
IPC分类号： C12Q1/02 , G01N33/52 , G01N33/68 , C12N15/85
CPC分类号： C12Q1/025 , C12N15/85 , G01N33/52 , G01N33/6872 , G01N2333/4719
摘要： The present invention relates to a method for evaluating the activity of a G protein receptor 43 (GPR43) activity control material. Specifically, a cell line which can measure cAMP having the concentration be changed upon the activity of GPR43 is developed. A cell line expressed by fusion of GPR43 and GFP is invented by using the properties in which the GPR43 is moved into cells when activated. Also, a cell line expressed by fusing fragments of luciferase with each of GPR43 and beta-arrestin2 is invented by using the properties in which the GPR43 binds to beta-arrestin2 when activated. Therefore, the cell line is useful in evaluation of the activity of a GPR43 activity control material.
摘要翻译：本发明涉及评价G蛋白受体43（GPR43）活性控制材料的活性的方法。具体地说，可以测量能够测量具有GPR43活性的浓度的cAMP的细胞系。通过GPR43和GFP融合表达的细胞系通过使用GPR43在激活时移入细胞的性质来发明。此外，通过使用GPR43结合β-抑制蛋白2的活性时的特性，发现通过融合萤光素酶片段与GPR43和β-抑制蛋白2各自融合而表达的细胞系。因此，细胞系可用于评估GPR43活性控制材料的活性。

5. 发明授权

KR101101245B1 리폭시제나아제에 대한 저해 활성을 갖는 신규 퓨린유도체 화합물, 이의 제조방법 및 이를 포함하는 천식의치료 및 예방용 조성물 有权
标题翻译：具有脂氧合酶抑制活性的新型嘌呤化合物及其制备方法以及含有该氧化酶预防和治疗哮喘的组合物
公开(公告)号：KR101101245B1
公开(公告)日：2012-01-04
申请号：KR1020050007301
申请日：2005-01-26
申请人： 한국생명공학연구원
发明人： 한균희 , 이진하 , 남기엽 , 박혜영 , 송현민 , 최석준 , 김건철 , 이기연 , 김주헌 , 김소영 , 정지연 , 이형규 , 오세량 , 민병선 , 안경섭 , 이상구 , 천태규 , 박보영 , 권옥경 , 김정희 , 김은아 , 최순자 , 김두영
IPC分类号： C07D473/40
摘要： 본 발명은 리폭시제나아제(Lipoxygenase)에 대한 저해활성을 갖는 신규 퓨린 유도체 (Ⅰ) 화합물, 이의 제조방법 및 이를 포함하는 천식 치료 및 예방용 조성물을 제공한다.
본 발명에 따른 화합물은 리폭시제나아제에 대해 강한 저해활성을 나타내므로, 이를 함유하는 조성물은 천식의 치료를 위한 약제로써 이용가능하다.

리폭시제나아제, 저해활성, 천식, 퓨린, 유도체

6. 发明公开

KR1020110055922A 아크릴아마이드 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물 失效
标题翻译：用于预防或治疗含有丙烯酰胺衍生物或药物可接受的作为活性成分的药物的炎症疾病的药物组合物
公开(公告)号：KR1020110055922A
公开(公告)日：2011-05-26
申请号：KR1020090112547
申请日：2009-11-20
申请人： 한국생명공학연구원
发明人： 이형규 , 오세량 , 안경섭 , 진영원 , 이상구 , 김두영 , 김수현 , 권옥경 , 육지은 , 이일수
IPC分类号： A61K31/165 , A61P29/00 , A61P11/06 , A61P37/08
摘要： PURPOSE: A pharmaceutical composition containing acrylamide derivatives is provided to suppress secretion or generation of leukotriene and to prevent and treat inflammatory diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating inflammatory diseases contains an acrylamide derivative of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In chemical formula 1, R is hydrogen or alkoxy of C1-C4. The acrylamide derivative of chemical formula 1 is (E)-4'-hydroxy-3'-methoxystyryl 3-(4-hydroxyphenyl)propanoate or (R,E)-4'-hydroxy-3'-methoxystyryl-3-(4-hydroxyphenyl)-7-methoxypropanoate. A method for preparing the acrylamide derivatives comprises: a step of extracting Solanum nigrum with water, alcohol of C1-C4, or mixture solvent; a step of suspending the extract in the water and adding same amount of ethyl acetate to obtain an ethyl acetate fraction(first fraction); a step of performing silicagel column chromatography of the ethyl acetate fraction to obtain a second fraction(1-6); a step of performing silicagel column chromatography of the 5th fraction of the second fraction to obtain a third fraction(5-1~5-7); and a step of performing reverse phase-18 column chromatography.
摘要翻译：目的：提供含有丙烯酰胺衍生物的药物组合物，以抑制白细胞三烯的分泌或产生并预防和治疗炎性疾病。构成：用于预防或治疗炎性疾病的药物组合物含有化学式1的丙烯酰胺衍生物或其药学上可接受的盐作为活性成分。在化学式1中，R是氢或C1-C4的烷氧基。化学式1的丙烯酰胺衍生物是（E）-4'-羟基-3'-甲氧基苯乙烯基3-（4-羟基苯基）丙酸酯或（R，E）-4'-羟基-3'-甲氧基苯乙烯基-3-（4 羟基苯基）-7-甲氧基丙。制备丙烯酰胺衍生物的方法包括：用水，C1-C4的醇或混合溶剂提取茄子的步骤; 将提取物悬浮在水中并加入相同量的乙酸乙酯以获得乙酸乙酯级分（第一级分）的步骤; 进行乙酸乙酯级分的硅胶柱色谱以获得第二级分（1-6）的步骤; 进行第二级分的第5级的硅胶柱色谱以获得第三级分（5-1〜5-7）的步骤; 和进行反相18柱色谱的步骤。

7. 发明公开

KR1020100098208A Ｒｇ3 및 Ｒｈ2의 함량이 증가된 흑삼추출물의 제조방법 有权
标题翻译：黑金刚增加RG3和RH2内容及其制备方法
公开(公告)号：KR1020100098208A
公开(公告)日：2010-09-06
申请号：KR1020090017259
申请日：2009-02-27
申请人： 한국생명공학연구원
发明人： 김보연 , 이상구 , 안종석 , 신현중
IPC分类号： A23L19/00 , A23L2/04 , A61P35/00 , A61K36/258
CPC分类号： A23L19/03 , A23L2/04 , A23L33/105 , A23V2002/00 , A23V2250/21 , A23V2300/10 , A61K36/258
摘要： PURPOSE: A black ginseng with increased amount of Rg3 and Rh2 and a method for manufacturing the same are provided to obtain anticancer effect of a ginseng saponin component by alternately repeating a steaming process at a room pressure and at a high pressure. CONSTITUTION: A method for manufacturing a black ginseng with increased amount of Rg3 and Rh2 comprises the following steps: repeating a process of drying the ginseng at 50-70°C for 1-3 hours after steaming dried ginseng at 110°C for 1-3 hours 9 times; performing first and sixth steaming processes at 5-15 atm; and pulverizing the black ginseng with the increased amount of Rg3 and Rh2, adding water to the black ginseng, and extracting the black ginseng using alcohol with a carbon number of 1-4.
摘要翻译：目的：提供具有增加量的Rg3和Rh2的黑参和其制造方法，以通过在室压和高压下交替重复蒸汽处理来获得人参皂苷组分的抗癌作用。构成：用于制造具有增加量的Rg3和Rh2的黑参的方法包括以下步骤：在110℃下干燥人参，在50-70℃下重复干燥人参1-3小时， 3小时9次; 以5-15 atm进行第一和第六次蒸汽处理; 并用增加量的Rg3和Rh2粉碎黑参，向黑参加水，并用碳数为1-4的醇提取黑参。

8. 发明公开

KR1020100067300A 신규 스테로이드 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 약학적 조성물 有权
标题翻译：新型甾体化合物或其药学上可接受的盐，其制备方法和药物组合物，用于预防和治疗包含其中的作为活性成分的炎症疾病
公开(公告)号：KR1020100067300A
公开(公告)日：2010-06-21
申请号：KR1020080125789
申请日：2008-12-11
申请人： 한국생명공학연구원
发明人： 이형규 , 오세량 , 안경섭 , 이중구 , 이상구 , 김두영 , 채흥복 , 김수현 , 권옥경 , 이미영 , 육지은 , 이일수
IPC分类号： A61K31/56 , A61P29/00
CPC分类号： A61K31/58 , A61K2236/33 , A61K2236/55 , Y10S424/81 , Y10S514/826 , Y10S514/886
摘要： PURPOSE: A steroid compound and a pharmaceutical composition containing the same for preventing and treating inflammatory diseases are provided to suppress secretion or generation of leukotriene and to prevent and treat inflammation, allergy, and asthma. CONSTITUTION: A steroid compound is denoted by chemical formula 1. A method for preparing phenylpropanoate comprises: a step of extracting Solanum gingrum fruit with water, alcohol of C1-C4, or mixture thereof; a step of suspending the extract in water and adding ethylacetate to obtain ethylacetate fraction; a step of performing silica gel column chromatography of ethylacetate fraction enhancing polarity of hexane/ethylacetate mixture solvent to obtain a second fraction(1-6); a step of performing silica gel column chromatography of the fifth fraction among the second fraction with chloroform/methanol/water mixture solution to a third fraction; and a step of performing reverse phase-18 column chromatography with methanol/water mixture solvent. A pharmaceutical composition for preventing and treating inflammatory diseases contains steroid compound of chemical formula 1 or pharmaceutically acceptable salt as an active ingredient.
摘要翻译：目的：提供类固醇化合物和含有该类固醇化合物的预防和治疗炎性疾病的药物组合物，以抑制白细胞三烯的分泌或产生，并预防和治疗炎症，过敏和哮喘。构成：化学式1表示类固醇化合物。制备苯基丙酸酯的方法包括：用水，C1-C4的醇或其混合物提取茄子果胶的步骤; 将提取物悬浮在水中并加入乙酸乙酯以获得乙酸乙酯级分的步骤; 进行乙酸乙酯级分的硅胶柱色谱法提高己烷/乙酸乙酯混合溶剂的极性以获得第二级分（1-6）的步骤; 将第二馏分中的第五馏分的硅胶柱色谱用氯仿/甲醇/水混合溶液进行第三馏分的步骤; 和用甲醇/水混合溶剂进行反相18柱色谱的步骤。用于预防和治疗炎性疾病的药物组合物含有化学式1的类固醇化合物或其药学上可接受的盐作为活性成分。

9. 发明公开

KR1020100062449A 항알러지, 항염증 또는 항천식 활성을 가진 류코노스톡 메센테로이드 Ｅ―１을 함유하는 조성물 有权
标题翻译：包含具有抗过敏，抗炎和抗哮喘活性的LEUCONOSTOC MESENTEROIDES E-1的组合物
公开(公告)号：KR1020100062449A
公开(公告)日：2010-06-10
申请号：KR1020080121091
申请日：2008-12-02
申请人： 한국생명공학연구원
发明人： 이형규 , 안경섭 , 권옥경 , 이미영 , 김소영 , 오세량 , 이상구 , 이중구 , 육지은 , 김희성
IPC分类号： A61K35/66 , A61K35/744 , A23L33/00
CPC分类号： A61K35/66 , A23L33/00 , A61K35/744
摘要： PURPOSE: A composition containing Leuconostoc mesenteroide E-1 is provided to suppress cytokines(IL-4 and IL-13) synthesis and eosinocyte increase and to prevent and treat allergy, inflammation, and bronchial asthma. CONSTITUTION: A composition for preventing and treating allergy, inflammation, or asthma contains Leuconostoc mesenteroide E-1(deposit number KCTC 10724BP) as an active ingredient. The Leuconostoc mesenteroide E-1 is a strain isolated from Kefir grain and suppresses the number of inflammatory cells. The inflammatory cell is eosinocyte. Pharmaceutically effective amount of composition is administered for a patient with allergy, inflammation, or asthma. A health food for preventing and treating allergy, inflammation, or asthma contains Leuconostoc mesenteroide E-1 as an active ingredient.
摘要翻译：目的：提供含有明串珠菌肠炎E-1的组合物，以抑制细胞因子（IL-4和IL-13）的合成和滋养细胞增加，并预防和治疗过敏，炎症和支气管哮喘。构成：用于预防和治疗过敏，炎症或哮喘的组合物含有肠系膜旁串珠菌E-1（保藏号KCTC 10724BP）作为活性成分。肠膜明串珠菌E-1是从Kefir颗粒分离的菌株，并抑制炎性细胞的数量。炎症细胞是嗜酸粒细胞。为具有过敏，炎症或哮喘的患者施用药物有效量的组合物。用于预防和治疗过敏，炎症或哮喘的保健食品含有明串珠菌肠炎E-1作为活性成分。

10. 发明公开

KR1020090087208A 신규 크라이토싸이빈 유도체, 이의 제조방법 및 이를유효성분으로 함유하는 노화방지용 조성물 有权
标题翻译：新型粘蛋白衍生物，其制备方法及其组合物，用于防止老化作为活性成分
公开(公告)号：KR1020090087208A
公开(公告)日：2009-08-17
申请号：KR1020080012510
申请日：2008-02-12
申请人： 한국생명공학연구원
发明人： 유익동 , 류인자 , 김영희 , 추수진 , 이상구
IPC分类号： C07D209/46 , A61K31/4035 , A61P39/06
CPC分类号： A61K8/492 , A61K8/9706 , A61K8/99 , A61K2800/80 , A61Q17/04 , A61Q19/004
摘要： A novel clitocybin derivative is provided to have the effects of removing radical and reducing DNA damage and erythema and prevent and treat diseases caused by excessive accumulation of active oxygen. A novel clitocybin derivative is denoted by the chemical formula 1. In the chemical formula 1, R1 and R2 is independently or selectively OCH3 or OH. A method for producing the clitocybin derivative of the chemical formula 1 comprises: a step one of culturing Clitocybe aurantiaca (KCTC 11143BP) to obtain culture product; a step two of extracting with acetone and ethylacetate; a step three of performing concentration gradient silica gel column chromatography to obtain active fraction; and a step four of performing Sephadex LH-20 column chromatography.
摘要翻译：提供了一种新的胞质胞质衍生物，具有去除自由基和减少DNA损伤和红斑的效果，并预防和治疗由活性氧过度积累引起的疾病。化学式1表示新的胞质胞质衍生物。在化学式1中，R 1和R 2独立地或选自OCH 3或OH。制备化学式1的胞质胞苷衍生物的方法包括：培养嗜铬嗜球赤霉菌（KCTC 11143BP）以获得培养产物的步骤之一; 用丙酮和乙酸乙酯提取第二步; 第三步进行浓缩梯度硅胶柱层析，得到活性组分; 和进行Sephadex LH-20柱色谱的第四步。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式